{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:43:43Z","timestamp":1790747023988,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic kidney disease (CKD) is a risk factor for cardiovascular (CV) events in patients with heart failure (HF). It is unclear whether type 2 diabetes (T2D), closely intertwined with both HF and CKD, modifies the association between cardiovascular outcomes and CKD in HF patients, and whether this association differs according to ejection fraction (EF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      HF patients enrolled in the Swedish Heart Failure Registry from January 2017 to December 2021 were analyzed. Linkage with the National Diabetes Registry and other population registries provided extensive baseline information. Patients were stratified by T2D status and CKD stages, defined by estimated glomerular filtration rate (eGFR: &lt;30, 30\u201344, 45\u201359, \u2265\u200960\u00a0ml\/min\/1.73\u00a0m\n                      <jats:sup>2<\/jats:sup>\n                      ). The primary outcome was the composite of time to first HF hospitalization (HHF) or CV death. Secondary outcomes were major adverse CV events (MACE, i.e. CV death, non-fatal myocardial infarction and stroke), CV death and all-cause death. Multivariable Cox regression models assessed the associations between eGFR and outcomes according to T2D, including interaction testing. A subgroup analysis was conducted by EF.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 36,597 patients included, 8,053 (22%) had T2D, 23,562 (64.4%), 7122 (19.4%), 4477 (12.2%), 1436 (4.0%), were in the four eGFR categories (eGFR\u2009\u2265\u200960, 45\u201359, 30\u201344, and &lt;\u200930 mL\/min\/1.73\u00a0m\n                      <jats:sup>2<\/jats:sup>\n                      , respectively), and 53%, 25%, 22% had HF with reduced, mildly-reduced, and preserved EF, respectively. Across eGFR, patients with vs. without T2D were younger, more often male, with higher CV comorbidity and more frequent use of cardio-renal drugs. Across EF categories, T2D patients had higher prevalence of CKD. Lower eGFR categories were progressively associated with higher risk of the primary outcome, independently of T2D. This was consistent across EF, except in HFpEF with eGFR\u2009&lt;\u200930\u00a0ml\/min\/1.73\u00a0m\n                      <jats:sup>2<\/jats:sup>\n                      , where the magnitude of the association in T2D group was smaller than in non-T2D (\n                      <jats:italic>p<\/jats:italic>\n                      -interaction\u2009&lt;\u20090.01). Risks of MACE, CV death and all-cause mortality were higher for lower eGFR categories, with lower hazards in T2D group (\n                      <jats:italic>p<\/jats:italic>\n                      -interaction\u2009&lt;\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a contemporary HF cohort, decreased kidney function was associated with a progressively higher risk of HHF\/CV death, and T2D was not a risk modifier. Renal protection should therefore be implemented in HF regardless of T2D.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-025-02998-w","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T12:13:59Z","timestamp":1764591239000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Impact of type 2 diabetes on the relationship between chronic kidney disease and cardiovascular outcomes in heart failure across ejection fraction: observational study from the Swedish heart failure and the Swedish National diabetes registries"],"prefix":"10.1186","volume":"24","author":[{"given":"Aurora","family":"Merolla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Valente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Basile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Benson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cosentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Dahlstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soffia","family":"Gudbj\u00f6rnsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Rovere-Querini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars H.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Savarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0318-7435","authenticated-orcid":false,"given":"Giulia","family":"Ferrannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"issue":"17","key":"2998_CR1","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","volume":"118","author":"G Savarese","year":"2023","unstructured":"Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272\u201387.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"2998_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000520909","volume":"12","author":"K Vijay","year":"2022","unstructured":"Vijay K, Neuen BL, Lerma EV. Heart failure in patients with diabetes and chronic kidney disease: challenges and opportunities. Cardiorenal Med. 2022;12(1):1\u201310.","journal-title":"Cardiorenal Med"},{"issue":"4","key":"2998_CR3","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.pcad.2019.07.003","volume":"62","author":"E Braunwald","year":"2019","unstructured":"Braunwald E. Diabetes, heart failure, and renal dysfunction: the vicious circles. Prog Cardiovasc Dis. 2019;62(4):298\u2013302.","journal-title":"Prog Cardiovasc Dis"},{"issue":"16","key":"2998_CR4","doi-asserted-by":"publisher","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","volume":"139","author":"J Rangaswami","year":"2019","unstructured":"Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019;139(16):e840\u201378.","journal-title":"Circulation"},{"issue":"3","key":"2998_CR5","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1161\/CIRCOUTCOMES.113.000221","volume":"6","author":"DH Smith","year":"2013","unstructured":"Smith DH, Thorp ML, Gurwitz JH, McManus DD, Goldberg RJ, Allen LA, et al. Chronic kidney disease and outcomes in heart failure with preserved versus reduced ejection fraction: the Cardiovascular Research Network PRESERVE study. Circ Cardiovasc Qual Outcomes. 2013;6(3):333\u201342.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"21","key":"2998_CR6","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1016\/j.jacc.2019.02.071","volume":"73","author":"N Bansal","year":"2019","unstructured":"Bansal N, Zelnick L, Bhat Z, Dobre M, He J, Lash J, et al. Burden and outcomes of heart failure hospitalizations in adults with chronic kidney disease. J Am Coll Cardiol. 2019;73(21):2691\u2013700.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"2998_CR7","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","volume":"29","author":"MR MacDonald","year":"2008","unstructured":"MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29(11):1377\u201385.","journal-title":"Eur Heart J"},{"key":"2998_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100739","volume":"32","author":"CA Lawson","year":"2021","unstructured":"Lawson CA, Seidu S, Zaccardi F, McCann G, Kadam UT, Davies MJ, et al. Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years. EClinicalMedicine. 2021;32:100739.","journal-title":"EClinicalMedicine"},{"issue":"9","key":"2998_CR9","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/ejhf.2421","volume":"24","author":"FR Mc Causland","year":"2022","unstructured":"Mc Causland FR, Lefkowitz MP, Claggett B, Packer M, Senni M, Gori M, et al. Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. Eur J Heart Fail. 2022;24(9):1591\u20138.","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"2998_CR10","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jchf.2021.06.017","volume":"9","author":"JJV McMurray","year":"2021","unstructured":"McMurray JJV, Wheeler DC, Stef\u00e1nsson BV, Jongs N, Postmus D, Correa-Rotter R, et al. Effects of Dapagliflozin in patients with kidney disease, with and without heart failure. JACC Heart Fail. 2021;9(11):807\u201320.","journal-title":"JACC Heart Fail"},{"issue":"16","key":"2998_CR11","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391(16):1475\u201385.","journal-title":"N Engl J Med"},{"issue":"1","key":"2998_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/03009734.2018.1490831","volume":"124","author":"G Savarese","year":"2019","unstructured":"Savarese G, Vasko P, Jonsson \u00c5, Edner M, Dahlstr\u00f6m U, Lund LH. The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure. Ups J Med Sci. 2019;124(1):65\u20139.","journal-title":"Ups J Med Sci"},{"key":"2998_CR13","unstructured":"\u00c5rsrapport 2022- Nationella Diabetesregistret [https:\/\/www.ndr.nu\/pdfs\/Arsrapport_NDR_2022.pdf]"},{"issue":"4S","key":"2998_CR14","first-page":"S117","volume":"105","author":"K Disease","year":"2024","unstructured":"Disease K. Improving Global Outcomes CKDWG: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117\u2013314.","journal-title":"Kidney Int"},{"issue":"9854","key":"2998_CR15","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","volume":"380","author":"CS Fox","year":"2012","unstructured":"Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380(9854):1662\u201373.","journal-title":"Lancet"},{"issue":"7","key":"2998_CR16","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","volume":"35","author":"K Damman","year":"2014","unstructured":"Damman K, Valente MA, Voors AA, O\u2019Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35(7):455\u201369.","journal-title":"Eur Heart J"},{"issue":"7","key":"2998_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158765","volume":"11","author":"NR Hill","year":"2016","unstructured":"Hill NR, Fatoba ST, Oke JL, Hirst JA, O\u2019Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease - a systematic review and meta-analysis. PLoS ONE. 2016;11(7):e0158765.","journal-title":"PLoS ONE"},{"issue":"1","key":"2998_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"CP Kovesdy","year":"2022","unstructured":"Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022;12(1):7\u201311.","journal-title":"Kidney Int Suppl"},{"issue":"9","key":"2998_CR19","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1161\/CIRCULATIONAHA.121.052792","volume":"145","author":"IE Beldhuis","year":"2022","unstructured":"Beldhuis IE, Lam CSP, Testani JM, Voors AA, Van Spall HGC, Ter Maaten JM, et al. Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease. Circulation. 2022;145(9):693\u2013712.","journal-title":"Circulation"},{"issue":"1","key":"2998_CR20","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s12882-025-04171-7","volume":"26","author":"TG Jenssen","year":"2025","unstructured":"Jenssen TG, Bodegard J, Sveen KA, Thuresson M, Birkeland KI. Prevalence, outcomes, costs, and treatments of a contemporary population with chronic kidney disease in Norway: a nationwide observational study. BMC Nephrol. 2025;26(1):393.","journal-title":"BMC Nephrol"},{"issue":"12","key":"2998_CR21","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/ejhf.813","volume":"19","author":"O Chioncel","year":"2017","unstructured":"Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC heart failure long-term registry. Eur J Heart Fail. 2017;19(12):1574\u201385.","journal-title":"Eur J Heart Fail"},{"key":"2998_CR22","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2023.03","volume":"9","author":"CJ Kapelios","year":"2023","unstructured":"Kapelios CJ, Shahim B, Lund LH, Savarese G. Epidemiology, clinical characteristics and cause-specific outcomes in heart failure with preserved ejection fraction. Card Fail Rev. 2023;9:e14.","journal-title":"Card Fail Rev"},{"issue":"12","key":"2998_CR23","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1002\/ejhf.821","volume":"19","author":"I L\u00f6fman","year":"2017","unstructured":"L\u00f6fman I, Szummer K, Dahlstr\u00f6m U, Jernberg T, Lund LH. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction. Eur J Heart Fail. 2017;19(12):1606\u201314.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"2998_CR24","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/ejhf.497","volume":"18","author":"JM Ter Maaten","year":"2016","unstructured":"Ter Maaten JM, Damman K, Verhaar MC, Paulus WJ, Duncker DJ, Cheng C, et al. Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. Eur J Heart Fail. 2016;18(6):588\u201398.","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"2998_CR25","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/ejhf.3112","volume":"26","author":"D Tomasoni","year":"2024","unstructured":"Tomasoni D, Vitale C, Guidetti F, Benson L, Braunschweig F, Dahlstrom U, et al. The role of multimorbidity in patients with heart failure across the left ventricular ejection fraction spectrum: data from the Swedish Heart Failure Registry. Eur J Heart Fail. 2024;26(4):854\u201368.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"2998_CR26","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jchf.2019.09.009","volume":"8","author":"JB Cohen","year":"2020","unstructured":"Cohen JB, Schrauben SJ, Zhao L, Basso MD, Cvijic ME, Li Z, et al. Clinical phenogroups in heart failure with preserved ejection fraction: detailed phenotypes, prognosis, and response to spironolactone. JACC Heart Fail. 2020;8(3):172\u201384.","journal-title":"JACC Heart Fail"},{"issue":"14","key":"2998_CR27","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1093\/eurheartj\/ehr254","volume":"33","author":"Meta-analysis Global Group in Chronic Heart F","year":"2012","unstructured":"Meta-analysis Global Group in Chronic Heart F. The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J. 2012;33(14):1750\u20137.","journal-title":"Eur Heart J"},{"issue":"48","key":"2998_CR28","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1093\/eurheartj\/ehu254","volume":"35","author":"M Gori","year":"2014","unstructured":"Gori M, Senni M, Gupta DK, Charytan DM, Kraigher-Krainer E, Pieske B, et al. Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. Eur Heart J. 2014;35(48):3442\u201351.","journal-title":"Eur Heart J"},{"issue":"1","key":"2998_CR29","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12933-023-02008-x","volume":"22","author":"A Ramezankhani","year":"2023","unstructured":"Ramezankhani A, Azizi F, Hadaegh F. Association between estimated glomerular filtration rate slope and cardiovascular disease among individuals with and without diabetes: a prospective cohort study. Cardiovasc Diabetol. 2023;22(1):270.","journal-title":"Cardiovasc Diabetol"},{"key":"2998_CR30","unstructured":"Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Johansen K, Kasiske B, Kutner N, Liu J, St Peter W et al: 'United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. In: Am J Kidney Dis. vol. 59. United States; 2012: A7, e1\u2013420."},{"issue":"15","key":"2998_CR31","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"2","key":"2998_CR32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327.","journal-title":"N Engl J Med"},{"issue":"8","key":"2998_CR33","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","volume":"145","author":"AM Shaman","year":"2022","unstructured":"Shaman AM, Bain SC, Bakris GL, Buse JB, Idorn T, Mahaffey KW, et al. Effect of the glucagon-like peptide-1 receptor agonists Semaglutide and Liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER. Circulation. 2022;145(8):575\u201385.","journal-title":"Circulation"},{"issue":"36","key":"2998_CR34","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"37","key":"2998_CR35","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627\u201339.","journal-title":"Eur Heart J"},{"key":"2998_CR36","unstructured":"Kosiborod MN, Abildstrom SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, Moller DV et al: Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med 2023."},{"issue":"10456","key":"2998_CR37","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","volume":"404","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Deanfield J, Pratley R, Borlaug BA, Butler J, Davies MJ, et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024;404(10456):949\u201361.","journal-title":"Lancet"},{"issue":"6","key":"2998_CR38","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474\u201384.","journal-title":"Eur Heart J"},{"key":"2998_CR39","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/ki.2013.243","volume":"84","author":"KM Andrassy","year":"2013","unstructured":"Andrassy KM. Comments on \u201cKDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.\u201d Kidney Int. 2013;84:622\u20133 (United States;).","journal-title":"Kidney Int"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02998-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02998-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02998-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T12:14:00Z","timestamp":1764591240000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02998-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2998"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02998-w","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"21 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical permits have been granted by the Swedish Ethical Review Authority.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"452"}}